Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06591013
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
None
First Post:
2024-07-17
Brief Title:
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Nationality in the Treatment of IBD
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease the Role of Selection of the Bai Nationality as Donor Source in Terms of Treatment Efficacy and Mechanisms
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Inflammatory bowel disease IBD is a chronic recurrent non-specific intestinal disease including ulcerative colitis UC and Crohns disease CD Although biological therapy significantly improved the effect of the treatment of ulcerative colitis but nearly two-thirds of the patients response to drug treatment Therefore new treatments targeting the underlying pathophysiology of UC are critical Given that alterations in the gut microbiome are strongly associated with disease activity in IBD many studies have proposed microbiotoy-based therapies in particular Fecal microbiota transplantation FMT in the treatment of UC Donor-to-donor variation in treatment with fecal microbiota transplantation may alter treatment efficacy Therefore screening high-quality donors can improve efficacy and minimize the risk of adverse effects
Detailed Description:
Ulcerative colitis with the changes in the gut microbiota and biodiversity decrease and the change of the relative abundance of advantage bacterium group a significant reduction in UC patients with intestinal flora diversity at the species level thick wall bacteria door bacteria eg clostridium tender ratio decreases actinomyces door the door deformation bacteria such as e coli enterobacteriaceae streptococcus bacteroides ratio increasedA previous study by team of the investigators found that there were ethnic and regional differences in the incidence of IBD in Yunnan Province and the incidence of Dai Bai and Miao was lower than that of Han Then the related factors were analyzed among which the ethnic characteristic diet of Yunnan ethnic minorities can improve the diversity of intestinal flora and viruses increase the content of probiotics and is a protective factor for the low incidence of UCBased on this donor-to-donor variation in the treatment of fecal microbiota transplantation may alter the therapeutic effect Therefore screening high-quality donors can improve efficacy and minimize the risk of adverse effectsBased on this the investigators asked scientific questions FMT in the treatment of IBD the Bai nationality of Yunnan province may be a high quality donorOur study is aims to FMT in the treatment of IBD the role of selection of the Bai nationality as donor source in terms of treatment efficacy and mechanisms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None